All the news Showing 10 of 46 articles from: Nucleotide Ns5B polymerase inhibitorsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Sofosbuvir + GS-5816 for 12 weeks shows high HCV cure rates, but 8 weeks is less effective for some patients Liz Highleyman / 02 December 2014 A 12-week oral combination of sofosbuvir plus the experimental NS5A inhibitor GS-5816 demonstrated high sustained virological response rates for people with difficult-to-treat HCV genotype 3 and other genotypes, according to phase 2 study ... Sofosbuvir/ledipasvir and AbbVie 2D regimen cure most people with HCV genotype 4 Liz Highleyman / 13 November 2014 [Editor's Note: this article previously stated that the PEARL-I trial tested the AbbVie 3D Viekira Pak regimen for HCV genotype 4. In actuality, the study used the 2D regimen consisting of the paritaprevir coformulation without dasabuvir. The article has been corrected.] Sofosbuvir/ledipasvir without ribavirin and ... Sofosbuvir/ledipasvir with ribavirin is highly effective for people with decompensated cirrhosis Liz Highleyman / 12 November 2014 An oral regimen of sofosbuvir/ledipasvir plus ribavirin taken for 12 weeks cured most hepatitis C patients with decompensated cirrhosis, the most advanced stage of liver disease, according to a presentation ... Sofosbuvir/ledipasvir safe and effective for genotype 1 HCV Liz Highleyman / 22 October 2014 A single-tablet regimen containing the hepatitis C virus (HCV) nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir – the combination in Gilead Science's recently approved Harvoni pill – was well-tolerated and cured 97% of patients with HCV genotype 1 in the Phase 3 ION trials, ... Sofosbuvir + ribavirin cures hepatitis C for more than 80% of people with HIV and HCV co-infection Liz Highleyman / 28 July 2014 An interferon-free regimen of sofosbuvir (Sovaldi) plus ribavirin for 24 weeks led to sustained hepatitis C virological response in 84 to 89% of HIV-positive people with chronic hepatitis C genotypes 1, 2, ... Sustained response to treatment reduces fatigue in people with hepatitis C Keith Alcorn / 30 May 2014 Curative treatment that eliminates hepatitis C virus (HCV) from the body can reduce central fatigue, one of the most concerning symptoms associated with chronic hepatitis C, according to research presented at the ... Sofosbuvir + ribavirin is safe and effective for HCV recurrence after liver transplantation Liz Highleyman / 29 May 2014 An interferon-free combination of sofosbuvir (Sovaldi) plus ribavirin taken for up to 24 weeks led to sustained virological response in 70% of liver transplant recipients with hepatitis C virus (HCV) recurrence, according to ... Sofosbuvir + ribavirin for 24 weeks is highly effective against HCV genotype 4 Liz Highleyman / 28 May 2014 A 24-week regimen of sofosbuvir (Sovaldi) plus ribavirin cured 93% of people with hard-to-treat hepatitis C virus genotype 4, though treatment for only 12 weeks was not as effective, according to a ... Sofosbuvir for hepatitis C works well despite multiple negative predictive factors Liz Highleyman / 24 April 2014 Hepatitis C treatment using sofosbuvir (Sovaldi) is highly effective even for people with multiple factors traditionally associated with poor response. Having four or more negative predictive factors, however, raises the risk of post-treatment relapse, ... Sofosbuvir + ribavirin is safe and effective for people with hepatitis C who have advanced liver disease Liz Highleyman / 17 April 2014 Sofosbuvir plus ribavirin is a safe option that can lead to sustained response in people with advanced liver disease including those with decompensated cirrhosis and portal hypertension, and people who experience severe hepatitis ... ← Prev12345Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive